Program
pevifoscorvir sodium
Also written as “ALG-000184” and “Pevifoscorvir Sodium (ALG-000184)”.
Its studies are mostly in Hepatitis B, Chronic, led by Aligos Therapeutics.
Furthest: phase 2, since Apr 22, 20255 company-led studies, 2 open or runningNext primary completion: Mar 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Aligos Therapeutics | 52 open or running | phase 2since Apr 22, 2025 | Aug 28, 2020 | Mar 2027phase 2 · NCT06963710 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 28, 2020First study: phase 1 study in Hepatitis B, ChronicFirst studyNCT04536337 · 165 enrolled · Australia, China, Hong Kong and more
- Sep 25, 2024Phase 1 study in Healthy VolunteerNCT06672900 · 24 enrolled · United States
- Apr 22, 2025Phase 2 study in Hepatitis B, ChronicNCT06963710 · 200 enrolled · United States, Bulgaria, Canada and more
- Dec 15, 20252 phase 1 studiesNCT07342881, NCT07342868
Ahead
- Mar 2027Primary completion: phase 2 study in Hepatitis B, ChronicNCT06963710
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07342881Hepatitis B, Chronic · United States | 1 | Completed | Jul 29, 2026 | 12 |
| NCT07342868Chronic Hepatitis B Infections · United States | 1 | Completed | Aug 19, 2026 | 20 |
| NCT06963710Hepatitis B, Chronic · United States, Bulgaria, Canada and more | 2 | Active, not recruiting | Mar 2027 | 200 |
| NCT06672900Healthy Volunteer · United States | 1 | Active, not recruiting | Jul 7, 2025 | 24 |
| NCT04536337Hepatitis B, Chronic · Australia, China, Hong Kong and more | 1 | Completed | Jun 16, 2025 | 165 |
How it is read
Names in the registry
- “ALG-000184”, 3 entries
- “Pevifoscorvir Sodium (ALG-000184)”, 2 entries
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.